Roche Holding 경영진

경영진 기준 점검 2/4

현재 CEO에 대한 정보가 충분하지 않습니다.

핵심 정보

Thomas Schinecker

최고경영자

n/a

총 보수

CEO 급여 비율	n/a
CEO 재임 기간	2.7yrs
CEO 지분 보유율	n/a
경영진 평균 재임 기간	6yrs
이사회 평균 재임 기간	7.2yrs

최근 경영진 업데이트

Recent updates

Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)

Aug 20

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Jun 24

Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025

Feb 02 Successful Pharma pipeline and innovative diagnostics launches are anticipated to drive long-term revenue growth and operating profit.

CEO 보수 분석

Thomas Schinecker의 보수는 Roche Holding의 수익에 비해 어떻게 변했나요?
날짜	총 보수	급여	회사 수익
Jun 30 2025	n/a	n/a	CHF 9b
Mar 31 2025	n/a	n/a	CHF 9b
Dec 31 2024	n/a	n/a	CHF 8b
Sep 30 2024	n/a	n/a	CHF 9b
Jun 30 2024	n/a	n/a	CHF 11b
Mar 31 2024	n/a	n/a	CHF 11b
Dec 31 2023	n/a	n/a	CHF 11b
Sep 30 2023	n/a	n/a	CHF 11b
Jun 30 2023	n/a	n/a	CHF 11b
Mar 31 2023	n/a	n/a	CHF 12b
Dec 31 2022	CHF 5m	CHF 1m	CHF 12b
Sep 30 2022	n/a	n/a	CHF 14b
Jun 30 2022	n/a	n/a	CHF 15b
Mar 31 2022	n/a	n/a	CHF 14b
Dec 31 2021	CHF 4m	CHF 1m	CHF 14b
Sep 30 2021	n/a	n/a	CHF 14b
Jun 30 2021	n/a	n/a	CHF 14b
Mar 31 2021	n/a	n/a	CHF 14b
Dec 31 2020	CHF 4m	CHF 879k	CHF 14b
Sep 30 2020	n/a	n/a	CHF 14b
Jun 30 2020	n/a	n/a	CHF 13b
Mar 31 2020	n/a	n/a	CHF 13b
Dec 31 2019	CHF 2m	CHF 609k	CHF 13b

보상 대 시장: Swiss 시장에서 비슷한 규모 기업과 비교해 Thomas의 총 보수가 적절한지 판단하기에 데이터가 부족합니다.

보상과 수익: Thomas의 보상은 20% 이상 증가했지만 지난 1년 동안 회사 수익은 20% 이상 감소했습니다.

CEO

Thomas Schinecker (50 yo)

2.7yrs

재임 기간

CHF 5,335,592

보수

Dr. Thomas Schinecker is Director since March 27, 2025 at Chugai Pharmaceutical Co., Ltd. He serves as Chairman of the Board at Genentech, Inc. since March 2023. He is Group Chief Executive Officer of Roch...

리더십 팀

이름	직위	재임 기간	보수	지분
Severin Schwan	Executive Chairman	12.7yrs	CHF 11.48m	데이터 없음
Thomas Schinecker	Group Chief Executive Officer	2.7yrs	CHF 5.34m	데이터 없음
Alan Hippe	Chief Financial Officer	14.6yrs	CHF 6.05m	데이터 없음
Bruno Eschli	Head of Investor Relations	no data	데이터 없음	데이터 없음
Claudia Bockstiegel	General Counsel	5.6yrs	데이터 없음	데이터 없음
Pascale Schmidt	Chief Compliance Officer	5.8yrs	데이터 없음	데이터 없음
Barbara Schadler	Head of Group Communications	6.1yrs	데이터 없음	데이터 없음
Maria Cristina Wilbur	Chief People Officer	9.7yrs	CHF 4.25m	데이터 없음
Nicolas Dunant	Head of Group Media Relations	no data	데이터 없음	데이터 없음
Boris L. Zaitra	Head of Corporate Business Development	no data	데이터 없음	데이터 없음
Cristin Hubbard	Senior Vice President of Immunology	no data	데이터 없음	데이터 없음
Sascha Fauser	Global Head of Ophthalmology Roche pRED	no data	데이터 없음	데이터 없음

6.0yrs

평균 재임 기간

58yo

평균 나이

경험이 풍부한 관리: ROG의 경영진은 노련하고 경험이 풍부합니다(평균 재임 6 년).

이사회 구성원

이름	직위	재임 기간	보수	지분
Severin Schwan	Executive Chairman	12.7yrs	CHF 11.48m	데이터 없음
Ulf Schneider	Director	2.7yrs	데이터 없음	데이터 없음
Andre Hoffmann	Independent Vice Chairman	29.8yrs	CHF 400.00k	데이터 없음
Patrick Frost	Independent Non Executive Director	5.7yrs	CHF 360.00k	데이터 없음
Richard Lifton	Non-Executive Independent Director	10.8yrs	CHF 346.71k	데이터 없음
Anita Hauser	Non-Executive Independent Director	8.7yrs	CHF 336.16k	데이터 없음
Jorg Duschmale	Non-Executive Independent Director	5.7yrs	CHF 394.60k	데이터 없음
Akiko Iwasaki	Director	2.7yrs	데이터 없음	데이터 없음
Claudia Ricarda Suessmuth Dyckerhoff	Non-Executive Independent Director	9.7yrs	CHF 367.02k	데이터 없음
Jemilah Mahmood	Independent Non-Executive Director	3.7yrs	CHF 272.50k	데이터 없음

7.2yrs

평균 재임 기간

58yo

평균 나이

경험이 풍부한 이사회: ROG의 이사회는 경험이 있음으로 간주됩니다(평균 재임 7.2 년).

기업 분석 및 재무 데이터 상태

데이터	최종 업데이트 (UTC 시간)
기업 분석	2025/11/28 12:37
종가	2025/11/28 00:00
수익	2025/06/30
연간 수익	2024/12/31

데이터 소스

당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
기업 재무제표	10년	손익계산서 현금흐름표 대차대조표	SEC 양식 10-K SEC 양식 10-Q
분석가 컨센서스 추정치	+3년	재무 예측 분석가 목표주가	분석가 리서치 보고서 Blue Matrix
시장 가격	30년	주가 배당, 분할 및 기타 조치	ICE 시장 데이터 SEC 양식 S-1
지분 구조	10년	주요 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
경영진	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발	10년	회사 공시	SEC 양식 8-K

^* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.

별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.

분석 모델 및 스노우플레이크

이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 Github 페이지에서 확인할 수 있으며, 보고서 활용 방법에 대한 가이드와 Youtube 튜토리얼도 제공합니다.

Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.

산업 및 섹터 지표

산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.

분석가 소스

Roche Holding AG는 50명의 분석가가 다루고 있습니다. 이 중 15명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.

분석가	기관
John Staszak	Argus Research Company
Gerhard Schwarz	Baader Helvea Equity Research
Mark Purcell	Barclays

Roche Holding 경영진

경영진 기준 점검 2/4

핵심 정보

최근 경영진 업데이트

Roche Announces Appointment of Nina Schwab-Hautzinger as Head of Group Communications and Member of the Enlarged Corporate Executive Committee, Effective 1 February 2026

Claudia Süssmuth Dyckerhoff Decides Not to Stand for Re-Election as a Member of the Roche Board of Directors

Roche Holding AG, Annual General Meeting, Sep 10, 2025

Roche Announces Management Changes

Roche Announces Executive and Committee Changes

Roche Announces Management and Board Committee Changes

Recent updates

European Commission Approves Roche's Lunsumio Subcutaneous for Relapsed or Refractory Foothicular Lymphoma

Roche's Giredestrant Becomes the First Oral SerD to Show Superior Invasive Disease-Free Survival in Early Breast Cancer

Roche's Fenebrutinib Shows Unprecedented Positive Phase III Results as the Potential First and Only BTK Inhibitor in Both Relapsing and Primary Progressive Multiple Sclerosis

Roche to Present New Data from its Broad and Innovative Haematology Portfolio at ASH 2025

Roche Announces Positive Phase III Data for Roche’s Gazyva/Gazyvaro Show Significant Reduction in Disease Activity for Systemic Lupus Erythematosus

Roche Holding AG (SWX:ROG) completed the acquisition of 89bio, Inc. (NasdaqGM:ETNB) in a tender offer transaction.

Roche Announces Positive Phase III Results for Gazyva/Gazyvaro in Children and Young Adults with Idiopathic Nephrotic Syndrome

Roche Announces Appointment of Nina Schwab-Hautzinger as Head of Group Communications and Member of the Enlarged Corporate Executive Committee, Effective 1 February 2026

Cmedsir Announces the Positive Results of Its Empress Study, Conducted in Collaboration with Roche Farma

FDA Approves Genentech's Gazyva for the Treatment of Lupus Nephritis

Roche’s Phase III evERA Data Showed Giredestrant Significantly Improved Progression-Free Survival in People with ER-Positive Advanced Breast Cancer

Roche Presents New Phase III Pivotal Data for Vamikibart in Uveitic Macular Edema

CHMP Recommends EU Approval of Roche's Gazyva/Gazyvaro for Lupus Nephritis

Roche Receives CE Mark for AI-Based Kidney Klin Risk Algorithm and Launches New Comprehensive Chronic Kidney Disease (CKD) Algorithm Panel

Claudia Süssmuth Dyckerhoff Decides Not to Stand for Re-Election as a Member of the Roche Board of Directors

Roche Announces Primary Results from the TSIX Study Program

Roche Presents New Data for OCREVUS and Fenebrutinib Across Broad Patient Populations at ECTRIMS 2025

Roche S.A. Announces Positive Phase III Results Show Roche's Giredestrant Significantly Improved Pro progression-Free Survival in ER-Positive Advanced Breast Cancer

CHMP Recommends EU Approval of Roche's Subcutaneous Formulation of Lunsumio for People with Relapsed or Refractory Follicular Lymphoma

Roche Achieves First CLIA 'Moderate Complexity' categorization for Ionify®? 25-Hydroxy Vitamin D Total Test

Roche Announces New Data Reinforcing Efficacy and Safety of Vabysmo in Treating nAMD

Investors Still Waiting For A Pull Back In Roche Holding AG (VTX:ROG)

Roche's First Respiratory Test Powered by TAGS Technology Receives FDA Clearance for SARS-CoV-2, Influenza A, Influenza B and RSV

First half 2025 earnings released: EPS: CHF9.31 (vs CHF7.85 in 1H 2024)

Roche Announces its New Innovations In-Booth at Association for Diagnostics & Laboratory Medicine Scientific Meeting and Clinical Lab Expo

These 4 Measures Indicate That Roche Holding (VTX:ROG) Is Using Debt Reasonably Well

Prothena's Partner Roche to Advance Prasinezumab into Phase III Development for Early-Stage Parkinson's Disease

Genentech Provides Update on FDA Advisory Committee Meeting on Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Holding AG, Annual General Meeting, Sep 10, 2025

Investor sentiment deteriorates as stock falls 15%

Roche Present Novel Therapeutic and Diagnostic Advancements in Alzheimer's At Ad/Pd 2025

Roche Holding AG Provides Update on Phase III Ocrevus High Dose Study in People with Relapsing Multiple Sclerosis

Roche Holding AG Approves Dividend

Roche Announces Management Changes

Upcoming dividend of CHF9.70 per share

Roche Holding (VTX:ROG) Will Pay A Larger Dividend Than Last Year At CHF9.70

Roche Holding AG to Present New Data At the Muscular Dystrophy Association Conference from 16-19 March, 2025

Roche Holding (VTX:ROG) Has A Pretty Healthy Balance Sheet

Roche Announces CHMP Recommends EU Approval of Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Holding (VTX:ROG) Is Increasing Its Dividend To CHF9.70

Roche Unveils New Class of Next-Generation Sequencing with Its Novel Sequencing by Expansion Technology

Roche Elecsys sFlt-1/PlGF Ratio for Preeclampsia Receives FDA 510(K) Clearance

Roche Holding (VTX:ROG) Is Paying Out A Larger Dividend Than Last Year

Legacy Pharma Inc. SEZC acquired InterMune, Inc. from Roche Holding AG (SWX:ROG).

Roche Holding's (VTX:ROG) Soft Earnings Are Actually Better Than They Appear

Roche Announces FDA Approves Roche’s Susvimo as the First and Only Continuous Delivery Treatment for the Leading Cause of Diabetes-Related Blindness

Roche Holding will see a 4.2576% revenue growth shaking the market

Advancing 7 New Therapies And Poseida Acquisition Will Expand Presence In Oncology By 2025

Full year 2024 earnings: EPS misses analyst expectations

Roche Receives FDA Approval for the First Companion Diagnostic to Identify Patients with HER2-ultralow Metastatic Breast Cancer Eligible for ENHERTU

Roche Holding AG Reports Earnings Guidance for the Year 2025

Roche Announces Executive and Committee Changes

Roche's Itovebi Demonstrates Statically Significant and clinically meaningful Overall Survival Benefit in A Certain Type of HR-Positive Advanced Breast Cancer

Roche Receives FDA Clearance with CLIA Waiver for Cobas® liat Molecular Tests to Diagnose Sexually Transmitted Infections At the Point of Care

Roche Receives FDA Clearance For VENTANA DP 600 Slide Scanner In Digital Pathology

Roche Holding AG to Report Fiscal Year 2024 Results on Jan 30, 2025

Roche's Vabysmo® Prefilled Syringe Approved by European Medicines Agency for Treating Retinal Conditions

New and Updated Data for Columvi and Lunsumio At Ash 2024 Reinforce Their Potential to Improve Outcomes for People with Lymphoma

Five-Year Results Confirm Roche’s Polivy Combination Therapy as New Standard of Care for Previously Untreated Aggressive Lymphoma

U.S. Food and Drug Administration Accepts Supplemental Biologics License Application for Roche’s Columvi Combination for People with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Roche Receives FDA Approval for First Companion Diagnostic to Identify Patients with Biliary Tract Cancer Eligible for Her2-Targeted Treatment with ZIIHERA

Roche to Present New and Encouraging Long-Term Follow-Up Data Across Broad Haematology Portfolio At ASH 2024

Roche Presents New Data At CTAD, Demonstrating Its Growing Momentum in Diagnostics for Alzheimer’s Disease

Roche Announces Positive Topline One-Year Results from the Open-Label, Single-Arm Phase IV ELEVATUM Study Evaluating Vabysmo® (Faricimab) for the Treatment of Diabetic Macular Edema (DME) in People from Racial and Ethnic Groups That Are Often Underrepresented in Clinical Trials

Roche Presents Positive Two-Year Data from the Ongoing Rainbowfish Study

FDA Approves Roche’s Itovebi, A Targeted Treatment for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer with A PIK3CA Mutation

Lonza Group AG (SWX:LONN) completed the acquisition of Genentech Manufacturing Facility in Vacaville, California from Roche Holding AG (SWX:ROG).

Halozyme Therapeutics, Inc. Announces FDA Approval of Roche's Subcutaneous OCREVUS ZUNOVO with ENHANZE for People with Relapsing and Primary Progressive Multiple Sclerosis

FDA Approves Roche’s Tecentriq Hybreza, the First and Only Subcutaneous Anti-PD-(L)1 Cancer Immunotherapy